Drug-induced liver injury (DILI) poses a significant health and economic burden in the
modern health care system. 1 Despite the advancements in health care, DILI is often a …

Cholestasis, defined as the impairment of bile flow/production, is a wellrecognized
presentation of drug-induced liver disease. There are insufficient data in the United States …

Cholestatic drug‐induced liver injury (DILI) can be a diagnostic challenge due to a large
differential diagnosis, variability in clinical presentation, and lack of serologic biomarkers …

Drugs may cause several overlapping syndromes of cholestasis, the pathophysiological
syndrome resulting from impaired bile flow. These reactions comprise approximately 17% of …

Cholestasis caused by medicinal and chemical agents is an increasingly well-recognized
cause of liver disease. Clinical drug-induced cholestatic syndromes producing jaundice and …

Cholestasis due to drugs is important in the differential diagnosis of patients presenting with
a biochemical cholestatic pattern and normal hepatobiliary imaging. The extent of …

Cholestasis resulting from medicinal and chemical agents is an increasingly well-
recognized cause of liver disease. Although the consequences of cholestatic injury are …

Intrahepatic cholestasis, defined as arrested bile flow, mimics extrahepatic obstruction in its
biochemical, clinical and morphological features. It may be due to hepatocyte lesions of …

Aims The diagnosis of drug‐induced liver injury (DILI) is relatively complex and involves a
wide variety of drugs. The purpose of this study was to use algorithms to quickly screen DILI …

• The pattern of liver injury can be classified as hepatocellular (with predominantly aspartate
aminotransferase/alanine transaminase [AST/ALT] elevations), cholestatic (with …